FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2061679424> ?p ?o ?g. }

• W2061679424 endingPage "341" @default.
• W2061679424 startingPage "331" @default.
• W2061679424 abstract "Three acyclic nucleoside phosphonates (ANPs) have been formally approved for clinical use in the treatment of 1) cytomegalovirus retinitis in AIDS patients (cidofovir, by the intravenous route), 2) chronic hepatitis B virus (HBV) infections (adefovir dipivoxil, by the oral route), and 3) human immunodeficiency virus (HIV) infections (tenofovir disoproxil fumarate, by the oral route). The activity spectrum of cidofovir {(S)-1-[3-hydroxy-2-(phosphonomethoxy)propyl]cytosine [(S)-HPMPC)]}, like that of (S)-HPMPA {(S)-9-[3-hydroxy-2-(phosphonomethoxy)propyl]adenine} and (S)-HPMPDAP {(S)-9-[3-hydroxy-2-(phosphonomethoxy)propyl]-2,6-diaminopurine}, encompasses a broad spectrum of DNA viruses, including polyoma-, papilloma-, adeno-, herpes-, and poxviruses. Adefovir {9-[2-(phosphonomethoxy)ethyl]adenine (PMEA)} and tenofovir {(R)-9-[2-(phosphonomethoxy) propyl]adenine [(R)-PMPA)]} are particularly active against retroviruses (i.e., HIV) and hepadnaviruses (i.e., HBV); additionally, PMEA also shows activity against herpes- and poxviruses. We have recently identified a new class of ANPs, namely 6-[2-(phosphonomethoxy)alkoxy]-2,4-diaminopyrimidines, named, in analogy with their alkylpurine counterparts, HPMPO-DAPy, PMEO-DAPy, and (R)-PMPO-DAPy. These compounds exhibit an antiviral activity spectrum and potency that is similar to that of (S)-HPMPDAP, PMEA, and (R)-PMPA, respectively. Thus, PMEO-DAPy and (R)-PMPO-DAPy, akin to PMEA and (R)-PMPA, proved particularly active against HIV-1, HIV-2, and the murine retrovirus Moloney sarcoma virus (MSV). PMEO-DAPy and (R)-PMPO-DAPy also showed potent activity against both wild-type and lamivudine-resistant strains of HBV. HPMPO-DAPy was found to inhibit different poxviruses (i.e., vaccinia, cowpox, and orf) at a similar potency as cidofovir. HPMPO-DAPy also proved active against adenoviruses. In vivo, HPMPO-DAPy proved equipotent to cidofovir in suppressing vaccinia virus infection (tail lesion formation) in immunocompetent mice and promoting healing of disseminated vaccinia lesions in athymic-nude mice. The 6-[2-(phosphonomethoxy)alkoxy]-2,4-diaminopyrimidines offer substantial potential for the treatment of a broad range of retro-, hepadna-, herpes-, adeno-, and poxvirus infections." @default.
• W2061679424 created "2016-06-24" @default.
• W2061679424 creator A5016741562 @default.
• W2061679424 creator A5030479730 @default.
• W2061679424 creator A5030754665 @default.
• W2061679424 creator A5032585928 @default.
• W2061679424 creator A5036860979 @default.
• W2061679424 creator A5038319371 @default.
• W2061679424 creator A5040662398 @default.
• W2061679424 creator A5072438230 @default.
• W2061679424 creator A5081640914 @default.
• W2061679424 creator A5085228034 @default.
• W2061679424 creator A5089010495 @default.
• W2061679424 date "2005-04-01" @default.
• W2061679424 modified "2023-10-03" @default.
• W2061679424 title "ANTIVIRAL POTENTIAL OF A NEW GENERATION OF ACYCLIC NUCLEOSIDE PHOSPHONATES, THE 6-[2-(PHOSPHONOMETHOXY)ALKOXY]-2,4-DIAMINOPYRIMIDINES" @default.
• W2061679424 cites W1964346333 @default.
• W2061679424 cites W1972241043 @default.
• W2061679424 cites W1974599773 @default.
• W2061679424 cites W2011006965 @default.
• W2061679424 cites W2056779298 @default.
• W2061679424 cites W2069498928 @default.
• W2061679424 cites W2077704646 @default.
• W2061679424 cites W2089091270 @default.
• W2061679424 cites W2113125007 @default.
• W2061679424 cites W2114677995 @default.
• W2061679424 cites W2117539616 @default.
• W2061679424 cites W2145335579 @default.
• W2061679424 cites W2150423201 @default.
• W2061679424 cites W2167839024 @default.
• W2061679424 cites W2168652503 @default.
• W2061679424 doi "https://doi.org/10.1081/ncn-200059772" @default.
• W2061679424 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16247948" @default.
• W2061679424 hasPublicationYear "2005" @default.
• W2061679424 type Work @default.
• W2061679424 sameAs 2061679424 @default.
• W2061679424 citedByCount "70" @default.
• W2061679424 countsByYear W20616794242012 @default.
• W2061679424 countsByYear W20616794242013 @default.
• W2061679424 countsByYear W20616794242014 @default.
• W2061679424 countsByYear W20616794242015 @default.
• W2061679424 countsByYear W20616794242016 @default.
• W2061679424 countsByYear W20616794242018 @default.
• W2061679424 countsByYear W20616794242019 @default.
• W2061679424 countsByYear W20616794242020 @default.
• W2061679424 countsByYear W20616794242021 @default.
• W2061679424 countsByYear W20616794242022 @default.
• W2061679424 crossrefType "journal-article" @default.
• W2061679424 hasAuthorship W2061679424A5016741562 @default.
• W2061679424 hasAuthorship W2061679424A5030479730 @default.
• W2061679424 hasAuthorship W2061679424A5030754665 @default.
• W2061679424 hasAuthorship W2061679424A5032585928 @default.
• W2061679424 hasAuthorship W2061679424A5036860979 @default.
• W2061679424 hasAuthorship W2061679424A5038319371 @default.
• W2061679424 hasAuthorship W2061679424A5040662398 @default.
• W2061679424 hasAuthorship W2061679424A5072438230 @default.
• W2061679424 hasAuthorship W2061679424A5081640914 @default.
• W2061679424 hasAuthorship W2061679424A5085228034 @default.
• W2061679424 hasAuthorship W2061679424A5089010495 @default.
• W2061679424 hasConcept C159047783 @default.
• W2061679424 hasConcept C185592680 @default.
• W2061679424 hasConcept C2522874641 @default.
• W2061679424 hasConcept C2776023528 @default.
• W2061679424 hasConcept C2776543447 @default.
• W2061679424 hasConcept C2776824251 @default.
• W2061679424 hasConcept C2777333352 @default.
• W2061679424 hasConcept C2777869810 @default.
• W2061679424 hasConcept C2779517838 @default.
• W2061679424 hasConcept C2780593183 @default.
• W2061679424 hasConcept C54355233 @default.
• W2061679424 hasConcept C552990157 @default.
• W2061679424 hasConcept C71240020 @default.
• W2061679424 hasConcept C86803240 @default.
• W2061679424 hasConceptScore W2061679424C159047783 @default.
• W2061679424 hasConceptScore W2061679424C185592680 @default.
• W2061679424 hasConceptScore W2061679424C2522874641 @default.
• W2061679424 hasConceptScore W2061679424C2776023528 @default.
• W2061679424 hasConceptScore W2061679424C2776543447 @default.
• W2061679424 hasConceptScore W2061679424C2776824251 @default.
• W2061679424 hasConceptScore W2061679424C2777333352 @default.
• W2061679424 hasConceptScore W2061679424C2777869810 @default.
• W2061679424 hasConceptScore W2061679424C2779517838 @default.
• W2061679424 hasConceptScore W2061679424C2780593183 @default.
• W2061679424 hasConceptScore W2061679424C54355233 @default.
• W2061679424 hasConceptScore W2061679424C552990157 @default.
• W2061679424 hasConceptScore W2061679424C71240020 @default.
• W2061679424 hasConceptScore W2061679424C86803240 @default.
• W2061679424 hasIssue "5-7" @default.
• W2061679424 hasLocation W20616794241 @default.
• W2061679424 hasLocation W20616794242 @default.
• W2061679424 hasOpenAccess W2061679424 @default.
• W2061679424 hasPrimaryLocation W20616794241 @default.
• W2061679424 hasRelatedWork W1974674628 @default.
• W2061679424 hasRelatedWork W2023559661 @default.
• W2061679424 hasRelatedWork W2037833329 @default.
• W2061679424 hasRelatedWork W2039736893 @default.
• W2061679424 hasRelatedWork W2078503670 @default.
• W2061679424 hasRelatedWork W2148748111 @default.

• next